Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.

V. R. Adams, T. Brenner

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.

Original languageEnglish
Pages (from-to)706-707
Number of pages2
JournalJournal of the American Pharmaceutical Association (Washington,D.C. : 1996)
Issue number5
StatePublished - 1999

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.'. Together they form a unique fingerprint.

Cite this